Is GKOS's Q1 2025 forecast achievable?

**Glaukos Corporation's (GKOS) Q1 2025 forecast appears to be achievable**, based on the following points: 1. **Positive Analyst Ratings**: The consensus rating for GKOS is "Buy" with an average current price target of $179. This suggests that analysts are optimistic about the stock's future performance, which aligns with the forecast. 2. **Recent Performance and Growth Prospects**: GKOS has demonstrated robust growth, particularly in the glaucoma segment, and has made strategic moves to integrate its iDose product. Despite facing some challenges, such as currency and reimbursement issues, the company has reported record sales and outlined strategic initiatives for 2025. 3. **Earnings Call Insights**: The Q4 2024 earnings call highlighted strong international performance and a growth outlook for 2025, despite some headwinds. The company's focus on strategic growth and ability to navigate market challenges suggest that the Q1 2025 forecast is attainable. 4. **Market Position and Innovation**: GKOS's leading position in the glaucoma segment and the potential of its iDose product to drive growth support the achievability of the forecast. In conclusion, while there may be challenges, the positive analyst ratings, recent performance, strategic initiatives, and market position of GKOS indicate that the Q1 2025 forecast is a realistic target.